Advertisement
BMY vs LLY
Which Stock Would AI Choose? Bristol-Myers Squibb (BMY) vs. Eli Lilly (LLY) Stock Comparison
Key Takeaways
- Bristol-Myers Squibb (BMY) has posted stronger year-to-date returns of approximately 20% compared to Eli Lilly (LLY)’s more modest gains of around 4% amid broader market conditions.
- LLY continues to benefit from exceptional revenue growth exceeding 47% year-over-year in its latest quarter, driven primarily by tirzepatide-based therapies for diabetes and obesity.
- BMY recently reported positive Phase 2 trial results for its investigational CAR T cell therapy in multiple myeloma and raised full-year guidance supported by Eliquis demand.
- Valuation metrics show BMY trading at a significantly lower forward price-to-earnings ratio near 10x versus LLY’s premium multiple above 27x, reflecting differing growth profiles.
- LLY completed a $3.8 billion acquisition in September 2026 to expand its neuroscience portfolio, while BMY emphasizes pipeline advancement in oncology and hematology.
- Relative performance highlights trade-offs between BMY’s stability and dividend yield near 3.7% and LLY’s higher growth trajectory with greater volatility.
Introduction
This comparison examines Bristol-Myers Squibb (BMY) and Eli Lilly (LLY), two major pharmaceutical companies with distinct business focuses within the healthcare sector. BMY maintains a diversified portfolio anchored by established products like Eliquis alongside emerging oncology assets, while LLY has positioned itself as a leader in metabolic and obesity treatments. Investors and traders seeking to understand relative performance, valuation differences, and sector-specific catalysts may find this analysis relevant for portfolio allocation decisions. The review emphasizes verifiable developments from recent market activity without projecting future outcomes.
BMY Overview and Recent Performance
Bristol-Myers Squibb (BMY) operates as a global biopharmaceutical company with key franchises in oncology, hematology, and cardiovascular care. In recent weeks, the stock has demonstrated resilience, building on year-to-date gains near 20% as of early September 2026. Positive momentum stemmed from second-quarter results that exceeded expectations, prompting an upward revision to full-year revenue and earnings guidance. Stronger-than-anticipated Eliquis sales, now projected to grow 20-25% for the year, helped offset legacy product declines. Additional support came from pipeline progress, including positive topline data from a registrational Phase 2 trial of arlocabtagene autoleucel, a GPRC5D-directed CAR T therapy for relapsed multiple myeloma announced around September 8. Market sentiment reflected measured optimism tied to execution across the growth portfolio, including products such as Reblozyl and Breyanzi, amid a broader large-cap pharma environment.
LLY Overview and Recent Performance
Eli Lilly (LLY) focuses on innovative medicines in diabetes, obesity, oncology, and neuroscience. The company delivered robust second-quarter revenue growth of approximately 48% year-over-year, fueled by tirzepatide products Mounjaro and Zepbound. In recent market activity, shares have experienced some pullback, with one-month declines near 8% as of mid-September 2026, following stronger longer-term gains of nearly 48% over the prior year. Sentiment has been influenced by continued commercial execution in the GLP-1 class alongside corporate development moves. On September 11, 2026, LLY completed the acquisition of AtaiBeckley for $3.8 billion, adding clinical-stage assets targeting treatment-resistant depression and other mental health conditions. This expansion complements earlier deals and supports diversification beyond metabolic therapies, though near-term price action reflected broader sector rotation and valuation considerations at elevated multiples.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots on its Trending AI Robots page. The platform offers hundreds of AI Trading Bots that trade thousands of different tickers across various market conditions. Only the best and most suitable bots for prevailing environments receive placement in this trending section. Available bots span a wide range of performance statistics, with historical win rates, profit factors, and drawdown metrics varying by strategy and timeframe. Each bot employs distinct trading styles, including trend-following, mean-reversion, and momentum approaches, along with different holding periods and ticker sets. Users can review detailed statistics and backtest data directly on the platform to identify options aligned with specific objectives.
Head-to-Head Comparison
Bristol-Myers Squibb (BMY) and Eli Lilly (LLY) differ markedly in scale, growth drivers, and risk profiles. LLY operates with a market capitalization exceeding $1 trillion and derives primary momentum from high-growth GLP-1 therapies, delivering revenue expansion well above industry averages. In contrast, BMY, with a market cap near $130 billion, emphasizes a balanced portfolio that includes mature assets like Eliquis alongside targeted oncology advancements, resulting in more moderate but steadier top-line trends. Valuation contrasts are pronounced: BMY trades at a forward price-to-earnings ratio around 10x with a dividend yield near 3.7%, appealing to value-oriented participants, while LLY commands a premium multiple above 27x reflecting its growth trajectory. Recent momentum favors BMY’s pipeline catalysts and guidance raises, whereas LLY contends with short-term price pressure despite acquisition-driven expansion in neuroscience. Sector exposure overlaps in pharmaceuticals yet diverges in therapeutic focus, with BMY offering greater stability through lower beta and LLY presenting higher volatility tied to product concentration. Market sentiment reflects these trade-offs, with BMY viewed through a lens of defensive qualities and LLY positioned for sustained expansion potential.
Tickeron AI Verdict
Based on observable factors such as trend consistency, earnings stability, and near-term catalysts, Tickeron’s AI models indicate a probabilistic preference for Bristol-Myers Squibb (BMY) in the current environment. BMY’s recent guidance uplift, positive clinical readout, and lower valuation multiple provide measurable support relative to LLY’s elevated multiples and recent share-price softness. LLY retains strong positioning through its growth franchise and acquisition activity, though higher volatility introduces greater variability in short-term signals. This assessment draws solely from quantitative patterns and does not constitute investment guidance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Hold and LLY is a Hold.
| BMY | LLY | BMY / LLY | |
| Capitalization | 129B | 1.03T | 13% |
| EBITDA | 16.8B | 41.7B | 40% |
| Gain YTD | 20.858 | 7.799 | 267% |
| P/E Ratio | 13.89 | 38.70 | 36% |
| Revenue | 49.2B | 79.7B | 62% |
| Total Cash | 11.1B | 8.95B | 124% |
| Total Debt | 45.1B | 54.9B | 82% |
BMY | LLY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 88 | 80 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 39 Fair valued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 84 | 11 | |
SMR RATING 1..100 | 22 | 14 | |
PRICE GROWTH RATING 1..100 | 43 | 44 | |
P/E GROWTH RATING 1..100 | 71 | 69 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (39) in the Pharmaceuticals Major industry is in the same range as LLY (50). This means that BMY’s stock grew similarly to LLY’s over the last 12 months.
LLY's Profit vs Risk Rating (11) in the Pharmaceuticals Major industry is significantly better than the same rating for BMY (84). This means that LLY’s stock grew significantly faster than BMY’s over the last 12 months.
LLY's SMR Rating (14) in the Pharmaceuticals Major industry is in the same range as BMY (22). This means that LLY’s stock grew similarly to BMY’s over the last 12 months.
BMY's Price Growth Rating (43) in the Pharmaceuticals Major industry is in the same range as LLY (44). This means that BMY’s stock grew similarly to LLY’s over the last 12 months.
LLY's P/E Growth Rating (69) in the Pharmaceuticals Major industry is in the same range as BMY (71). This means that LLY’s stock grew similarly to BMY’s over the last 12 months.
| BMY | LLY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 48% | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 60% | 2 days ago 75% |
| Momentum ODDS (%) | 2 days ago 55% | 2 days ago 56% |
| MACD ODDS (%) | 2 days ago 45% | 2 days ago 44% |
| TrendWeek ODDS (%) | 2 days ago 53% | 2 days ago 70% |
| TrendMonth ODDS (%) | 2 days ago 55% | 2 days ago 58% |
| Advances ODDS (%) | 17 days ago 57% | 2 days ago 70% |
| Declines ODDS (%) | 3 days ago 53% | 9 days ago 54% |
| BollingerBands ODDS (%) | 2 days ago 64% | 2 days ago 61% |
| Aroon ODDS (%) | 2 days ago 55% | 2 days ago 62% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BMY’s FA Score shows that 1 FA rating(s) are green while LLY’s FA Score has 2 green FA rating(s).
- BMY’s FA Score: 1 green, 4 red.
- LLY’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BMY’s TA Score shows that 4 TA indicator(s) are bullish while LLY’s TA Score has 3 bullish TA indicator(s).
- BMY’s TA Score: 4 bullish, 5 bearish.
- LLY’s TA Score: 3 bullish, 7 bearish.
Price Growth
BMY (@Pharmaceuticals: Major) experienced а -0.91% price change this week, while LLY (@Pharmaceuticals: Major) price change was +3.34% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.82%. For the same industry, the average monthly price growth was -6.21%, and the average quarterly price growth was +15.37%.
Reported Earning Dates
BMY is expected to report earnings on Oct 29, 2026.
LLY is expected to report earnings on Oct 29, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.82% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| GSPCX | 12.85 | 0.02 | +0.16% |
| Goldman Sachs Large Cap Equity C | |||
| ISCCX | 34.25 | -0.07 | -0.20% |
| Federated Hermes Intl Small-Mid Co C | |||
| CFIOX | 17.80 | -0.10 | -0.56% |
| Cantor Fitzgerald International Eq A | |||
| FCVIX | 21.04 | -0.13 | -0.61% |
| Fidelity Advisor Small Cap Value I | |||
| ARIIX | 10.86 | -0.11 | -1.00% |
| AB Global Real Estate Investment II I | |||
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with AMGN. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then AMGN could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | +0.35% | ||
| AMGN - BMY | 57% Loosely correlated | +1.55% | ||
| PFE - BMY | 57% Loosely correlated | +0.07% | ||
| NVS - BMY | 55% Loosely correlated | -0.39% | ||
| GSK - BMY | 53% Loosely correlated | -1.65% | ||
| ABBV - BMY | 51% Loosely correlated | -0.02% | ||
More | ||||